A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ

Meda Pharmaceuticals

Status: Completed

Conditions: Actinic Keratoses

Treatments: Drug: Imiquimod

Study type: Observational

Funder types: Industry

Identifiers

NCT00189254

1524-IMIQ

Details and patient eligibility

About

The purpose of the study is to obtain recurrence rates and long-term safety data for patients who had been treating actinic keratoses on the face and scalp with 5 % Imiquimod Cream in a previous study.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 100% clearance of Actinic Keratosis (AK) lesions in the 1487 IMIQ study

Exclusion criteria

• used any treatments in the previous treatment area within 24 hours prior to the follow-up visit

Trial design

72 participants in 1 patient group

Imiquimod 5% cream

Description:

No investigational treatments were given during this study.

Treatment:

Drug: Imiquimod